Physician profile
Jasmin Javaherian
NPI 1447294715
$326,618.69
in general payments reported to CMS, 2019-2025
73 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $18K · 2021: $54K · 2022: $62K · 2023: $30K · 2024: $25K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $41K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $4,600 · Consulting Fee: $1,125 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40,944.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,240.00 |
| Travel and Lodging | $4,599.91 |
| Consulting Fee | $1,125.00 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $51,593.48 | 2020-2025 | Nexletol, Nexlizet |
| Amgen INC. | $51,570.66 | 2019-2025 | Repatha, Repatha, Tepezza |
| Janssen Pharmaceuticals, INC | $47,268.25 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $31,534.50 | 2019-2020 | |
| Mannkind Corporation | $29,967.34 | 2019-2025 | Afrezza |
| Amarin Pharma, INC. | $22,064.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13,099.09 | 2019-2025 | Relistor, Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $8,302.55 | 2019-2025 | Dupixent |
| Mdd US Operations, LLC | $7,831.45 | 2019-2020 | |
| Abbvie INC. | $6,460.08 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,774.27 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $3,859.99 | 2019-2025 | Emgality, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $3,193.32 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sunovion Pharmaceuticals INC. | $2,881.24 | 2019-2022 | |
| Corcept Therapeutics | $2,664.92 | 2019-2023 | Korlym |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $2,532.62 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,330.43 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Mylan Specialty L.P. | $2,197.35 | 2020-2024 | Yupelri |
| Neurocrine Biosciences, INC. | $2,019.01 | 2022-2025 | Ingrezza |
| Radius Health, INC. | $1,884.73 | 2023-2025 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,862.70 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $1,586.19 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $1,472.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,397.93 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $1,366.47 | 2022-2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $1,302.90 | 2019-2023 | Tepezza |
| Phathom Pharmaceuticals, INC. | $1,286.77 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $1,264.05 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $1,199.52 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $1,102.58 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,101.59 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $975.86 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $965.05 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $963.78 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genzyme Corporation | $887.12 | 2022-2025 | |
| Leo Pharma INC. | $847.69 | 2023-2025 | Adbry |
| Azurity Pharmaceuticals, INC. | $761.66 | 2023-2025 | Horizant, Horizant, Alvesco |
| Allergan, INC. | $690.70 | 2019-2020 | |
| Uswm, LLC | $569.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $545.26 | 2020-2022 | |
| Gilead Sciences, INC. | $545.20 | 2019-2025 | |
| Ucb, INC. | $528.50 | 2021-2023 | Cimzia |
| Kvk-Tech, INC. | $506.72 | 2019 | |
| Almatica Pharma LLC | $463.23 | 2021-2024 | Loreev Xr, Teriparatide |
| Viatris Specialty LLC | $362.96 | 2025 | Yupelri |
| Astellas Pharma US INC | $347.40 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $312.60 | 2019-2023 | Belsomra, Steglatro |
| Eisai INC. | $301.70 | 2020-2022 | |
| Shire North American Group INC | $293.78 | 2019 | |
| Lundbeck LLC | $278.32 | 2025 | Rexulti |
| Pfizer INC. | $242.20 | 2019-2021 | |
| Shionogi INC | $233.96 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $201.95 | 2025 | |
| Dova Pharmaceuticals | $197.38 | 2019-2021 | |
| Axsome Therapeutics, INC. | $194.21 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $157.65 | 2022-2025 | Ztlido |
| Medicure Pharma INC. | $156.62 | 2021-2022 | |
| Verona Pharma, INC. | $155.41 | 2025 | Ohtuvayre |
| Ardelyx, INC. | $154.74 | 2025 | Ibsrela |
| Abbott Laboratories | $123.22 | 2021-2022 | |
| Dexcom, INC. | $116.57 | 2021 | |
| Biodelivery Sciences International, INC. | $115.41 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $85.95 | 2021-2022 | |
| Medtronic Minimed, INC. | $59.50 | 2019 | |
| Evofem Biosciences, INC. | $50.97 | 2021-2022 | |
| Redhill Biopharma INC. | $47.49 | 2022 | |
| Sandoz INC. | $42.36 | 2020-2021 | |
| Valinor Pharma, LLC | $36.51 | 2024 | Movantik |
| Sobi, INC | $33.28 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $25.47 | 2023 | Vivjoa |
| Idorsia Pharmaceuticals US INC | $24.40 | 2023 | Quviviq |
| Janssen Biotech, INC. | $23.77 | 2025 | Tremfya |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Javaherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.